BAAM
RVMD icon

Baker Avenue Asset Management’s Revolution Medicines RVMD Stock Holding History

Baker Avenue Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29
Closed -$803 – 1267
2023
Q3 		$803 Hold
29
– – ﹤0.01% 1331
2023
Q2 		$776 Hold
29
– – ﹤0.01% 1258
2023
Q1 		$628 Hold
29
– – ﹤0.01% 1337
2022
Q4 		$691 Buy
+29
New +$617 ﹤0.01% 1213

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Baker Avenue Asset Management's RVMD Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Revolution Medicines (RVMD) in Q4 2023, closing a stake of 29 shares — an estimated $803 sold.

Baker Avenue Asset Management first reported a position in RVMD in Q4 2022 and held it in 4 quarters. The position peaked at $803 in Q3 2023. 184 funds tracked by Wall St. Rank hold RVMD as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Revolution Medicines position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 29 Revolution Medicines shares in Q4 2023, an estimated $803.
  • Baker Avenue Asset Management first reported a position in Revolution Medicines in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Revolution Medicines position peaked at $803 in Q3 2023.
  • 184 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.